showed significant results. For AUCt, total amount of absorbed valsartan was 25,808 ± 6,863.0 ng․hr/mL , 20,683 ± 8,782.7 ng․hr/mL, and 12,502 ± 5,566.6 ng․hr/mL in responder, non-responder, and reverse responder, respectively (p = 0.041). In C max , maximum concentration of valsartan was 4,314 ± 1,522.6 ng/mL, 2,588 ± 1,273.9 ng/mL, and 2,056 ± 1,075.5 ng/mL, respectively. Conclusions: These results showed that response to valsartan was not associated with blood concentration in healthy volunteers and changes in blood pressure patterns to valsartan might be associated with the amount of drugs which are absorbed to subjects.
time required to reach maximum plasma concentration (T max ) were analyzed.
The results of 24-hour blood pressure monitoring were used for further pharmacokinetic-pharmacodynamic analysis. Pre-and post-dose changes in blood pressure were matched to valsartan concentration and analyzed by Pearson correlation coefficient test. Pre-and post-dose changes in blood pressure patterns were also analyzed.
Subjects and methods

Subjects
Twenty-one healthy Korean male volunteers aged 20 to 45 years were enrolled in the study. Subjects underwent screening examinations including a medical history, physical examination, and laboratory tests (hematology, clinical chemistry, and urinalysis). Exclusion criteria included medically documented conditions, including cardiovascular, respiratory, renal, hepatic, or gastrointestinal disorders; a chronic disorder that might influence the absorption, disposition, metabolism, or excretion of valsartan; a history of disturbances of organ or acute illness; a history of hematologic disorder or blood donation within 2 months; a history of blood fraction donation within 1 month; a history of psychiatric disorder; a history of drug hypersensitivity; a history of alcohol or drug abuse; participation in another clinical trial within 3 months; consumption of over 5 glasses daily of beverages containing xanthine derivatives; smoking > 20 cigarettes daily; and use of any over-the-counter drug medication having the potential to affect the study results. The study purpose and procedures were explained before the study, and written informed consent was obtained from all subjects.
Study design and sample collection
The study was a single group, two-sequence, open label, pre-and post-comparison, with a 1-week washout between study days. The study protocol was reviewed by the institutional review board of Kyung Hee University Hospital. All study procedures were conducted in accordance with the principles of the Declaration of Helsinki and the Korean Good Clinical Practice guidelines.
Subjects were assigned to free of medication in the first period; in the second period, they received the valsartan 80 mg. In both periods, subjects were admitted to the Kyung Hee University Clinical Research Center at 5 p.m.
on the day before administration of valsartan or study initiation. They received a standardized dinner, and no food was permitted after 8 p.m. The next day, subjects received no drug (baseline) or valsartan (treatment) along with 240 mL of tap water. Food and water were prohibited during the first 4 hours after dosing. At 4 hours after the oral administration, all subjects were given standardized meals. The subjects were not allowed to remain in a supine position or to sleep until 8 hours after the oral administration. Blood samples (7 mL) for valsartan concentration determination were obtained through a 22-guage indwelling catheter in a forearm vein or by direct venipuncture before dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24-hour after dosing in each period. Each sample was collected in heparinized tubes.
The blood samples were centrifuged immediately (3,000 rpm, 10 minutes), and were frozen at -80°C until UPLC -MS/MS analysis.
Pharmacokinetic assessment
To determine the valsartan plasma concentration, ACQUITY UPLC (Waters, Milford, MA, USA)-QTRAP 5500 (AB SCIEX, Foster City, CA, USA) were used as UPLC-ESI-MS/MS method.
11) The chromatographic separation was performed on a 2. 
Pharmacodynamic assessment
Twenty four hours blood pressure changes were monitored by ABPM. ABPM can provide a 24-hour blood pressure profile and blood pressure information over 24-hour as well as during specific periods, such as daytime, nighttime, and early morning. 7) The ABPM measurement was done according to "Guideline for blood Table 2 . Groups according to response to valsartan
Group assignment
The blood pressure patterns were classified as non-dipper, dipper, extreme-dipper, and reverse-dipper ( Table 1 ).
Subjects that diurnal blood pressure pattern changed from reverse dipper to non-dipper or dipper and changed from non-dipper to dipper or extreme dipper were assigned to responder group; subjects that have no change in diurnal blood pressure pattern were assigned to non-responder group; subjects that diurnal blood pressure pattern changed from non-dipper to reverse dipper and changed from dipper to non-dipper were assigned to reverse-responder group (Table 2 ).
Tolerability
Adverse events (AEs) were monitored throughout the study based on spontaneous reports by volunteers, questioning by investigators, and clinical examinations. The investigators assessed all clinical adverse effects in terms of intensity (mild, moderate, or severe), duration, outcome, and relationship to the study drug.
Statistical analysis
Pre-and post-dose blood pressure changes matched to All analysis were performed at an α level of 0.05.
Results
Subjects
Twenty-one healthy Korean male volunteers were participated. The mean (standard deviation, SD) age, height, and weight of subjects were 25.3 ± 3.5 years, 175.0 ± 3.9 cm, and 68.5 ± 7.8 kg, respectively.
Twenty-four hours blood pressure monitoring data was summarized in Table 3 .
Pre-and post-dose changes in blood pressure and pharmacokinetics
The ABPM results and pharmacokinetic parameters of each individual were summarized in Table 3 . Although all subjects were participated entire trial, ABPM data of Blood pressure (BP) data of subjects 2, 7, and 16 were lossed during trial. mSBP, mean systolic blood pressure; mDBP, mean diastolic blood pressure; mdSBP, mean daytime systolic blood pressure; mdDBP, mean daytime diastolic blood pressure; mnSBP, mean nighttime systolic blood pressure; mnDBP, mean nighttime diastolic blood pressure. AUCt, area under the plasma concentration versus time curve from 0 hour to the last measurable concentration; AUCinf, area under the plasma concentration versus time curve extrapolated to infinity; Cmax, maximum plasma concentration; Tmax, time required to reach maximum plasma concentration; BP, blood pressure; SD, standard deviation. Table 5 . Pharmacokinetic and pharmacodynamic properties of three groups post-dose from three subjects (R02, R07, and R16) was missed for various reasons. After finished 2nd period, 15 subjects showed decrease in mean SBP and 3 subjects showed increase in mean SBP. To associate pharmacokinetic parameters and changes in ABPM data, Pearson correlation analysis was conducted between ABPM data and pharmacokinetic parameters(C max , AUC t , and AUC inf ).
There were no significant associations between changes of ABPM data and pharmacokinetic parameters (Table 4) .
ABPM patterns and pharmacokinetics
The ABPM patterns and pharmacokinetic parameters of each individual were summarized in Table 5 . Ten, four, and seven subjects showed dipper, non-dipper, and reverse dipper pattern in 1st period, respectively. After finished 2nd period, eleven, one, and four subjects showed dipper, non-dipper, and reverse dipper pattern in 1st period, respectively. The mean AUC t (mean ± SD), total amount of absorbed valsartan was 25,808 ± 6,863.0 ng․ hr/mL, 20,683 ± 8,782.7 ng․hr/mL, and 12,502 ± 5,566.6 ng․hr/mL in responder, non-responder, and reverse responder, respectively. There were significant differences between mean AUC t of three groups (p = 0.041), and mean AUC t of responder group was significant higher 12,942 ± 5,589.2 ng·hr/mL in responder, non-responder, and reverse responder, respectively. There were significant differences between mean AUC inf of three groups (p = 0.025), and mean AUC t of responder group was significant higher than reverse group (p = 0.025, Turkey HSD). C max was 4,314 ± 1,522.6 ng/mL, 2,588 ± 1,273.9 ng/mL, and 2,056 ± 1,075.5 ng/mL in responder, non-responder, and reverse responder, respectively. There were significant differences between mean C max of three groups 
Tolerability
No serious AEs were reported, and no subjects discontinued the study due to AEs. But three subjects were failure to obtain ABPM data at the second period, and total 18 subjects were enrolled the statistical analysis.
Discussion
In pharmacotherapy, response of drug mainly depends on the amount of drug absorbed. Other factors, such as age, gender, genetic factor, and individual susceptibility affect the effect of drug. [9] [10] [11] [12] [13] In this study, we hypothesized that individual difference of valsartan effect mainly caused by amount of drug absorbed. So a single group, two-sequence, open label, pre-and post-comparison pharmacokinetic/pharmacodynamic (PK/PD) study was conducted. Total 21 subjects were enrolled and pre-and post-dose ABPM and pharmacokinetic data was used for PK/PD analysis.
We expected that blood pressure lowering effect of valsartan may be associated with amount of drug absorbed. Interestingly, three groups (responder, non-responder, and reverse responder) showed statistically different drug absorption pattern. In AUC t which represents amount of drug absorbed, three groups showed statistically different valsartan absorption. Especially, difference between responder and reverse-responder was more than two fold (25,808 ± 6,863.0 ng·hr/mL and 12,502 ± 5,566.6 ng·hr/mL in responder and reverse responder, respectively).
The maximum concentration of valsartan (C max ) also showed similar results.
These results showed that response to valsartan do not depend on amount of drug absorbed in this study.
Because this study has some limitations, if subject factors 
